Ainos Secures Ten Million Dollar Partnership Deal to Advance Key Drug Platform
San Diego, Thursday, 24 September 2026.
Biopharmaceutical firm Ainos signed a $10 million framework agreement with BioPhoenix, offloading expensive clinical trial costs for its drug platform while retaining core ownership and long-term commercial upside.
Strategic Licensing Agreement Announced
On September 24, 2026, biopharmaceutical company Ainos, Inc. (NASDAQ:AIMD, NASDAQ:AIMDW) announced a strategic licensing agreement with BioPhoenix Co., Ltd. [1]. This partnership establishes a collaboration framework with a potential aggregate value of $10 million for the VELDONA® therapy platform [1]. The agreement marks a significant milestone, transitioning the development of key indications to a partner-funded model while allowing Ainos to retain core platform ownership [1].
Capital-Eefficient Pipeline Progression
Under the terms of the agreement, BioPhoenix will finance and manage the clinical and regulatory advancement for two initial indications [1]. Ainos retains product supply rights and downstream commercial revenue participation, providing the company with capital-efficient pipeline progression [1]. This structure allows Ainos to reduce the capital and organizational resources it would otherwise need to commit directly to clinical trials and regulatory engagement [1].
Financial Framework and Revenue Potential
The $10 million figure represents a conditional framework rather than guaranteed revenue, comprising an initial license fee, conditional consideration for 15 additional indications, and a one-time sublicense fee [1]. This valuation excludes development expenditures funded by BioPhoenix, potential product supply revenue, and downstream revenue sharing [1]. BioPhoenix is obligated to pay a one-time fee within 30 days of the effective date of its first sublicense to a third party [1].
Commercial Participation Structure
Ainos is entitled to a 25% share of applicable net sublicensing revenue under the agreement terms [1]. Subsequent sublicenses do not trigger additional “first-sublicense” fees, focusing the financial upside on the initial transfer and revenue sharing [1]. This model enables shareholders to participate in the long-term value of the platform without shouldering the full burden of development costs [1].
Clinical Development and Indications
BioPhoenix holds an exclusive worldwide license for two initial indications: Sjögren’s disease and thrombocytopenia [1]. These areas cover research, development, manufacturing, marketing authorization, and commercialization responsibilities [1]. Potential additional indications for future licensing include Behçet’s disease, chronic fatigue syndrome, fibromyalgia, hepatitis B, hepatitis C, and idiopathic pulmonary fibrosis [1].
Platform History and Research Basis
The VELDONA platform is supported by approximately 40 years of research, encompassing 68 clinical studies [1]. The therapy is a low-dose oral interferon alpha treatment designed for administration via the oral mucosa [1]. This extensive background provides a foundational basis for the current development efforts being undertaken by BioPhoenix [1].
Strategic Implications and Leadership
Eddy Tsai, Chairman, President and Chief Executive Officer of Ainos, stated that the strategic value extends beyond the contemplated license consideration [1]. He noted that clinical trials, CRO oversight, regulatory engagement, and marketing authorization applications require sustained funding and specialized expertise [1]. Through this collaboration, the company aims to advance VELDONA through a partner-funded development model [1].
Long-Term Value and Ownership
The agreement ensures Ainos maintains ownership of the platform and participation in its future commercial value [1]. By combining partner-funded development with continued ownership, the company seeks to enable shareholders to participate in long-term value creation [1]. This approach balances immediate capital relief with retention of future licensing and commercialization opportunities [1].